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Inhibitors of the cyclo-oxygenase component of prostaglandin-H2 synthetase, namely indomethacin and ibuprofen, are
commonly used in the treatment of hemodynamically significant patent ductus arteriosus. These drugs are associated
with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol,
an inhibitor of the peroxidase component of prostaglandin-H2 synthetase, has been proposed for the treatment of
patent ductus arteriosus. We report a series of 8 neonates (birth weight: 724 ± 173 g; gestational age: 26 ± 2 weeks)
treated with paracetamol for a hemodynamically significant patent ductus arteriosus, because of contraindications to
ibuprofen or indomethacin. Successful closure was achieved in 6 out of 8 babies (75%). Median ductal diameter was
significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). No
adverse or side effects were observed during treatment. On the basis of these results, paracetamol could be considered
a promising and safe therapy for the treatment of patent ductus arteriosus in neonates.
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A persistently patent ductus arteriosus (PDA) has signifi-
cant clinical consequences in preterm neonates during
the recovery period from respiratory distress syndrome
[1]. Ductal patency is regulated by the circulating prosta-
glandins (PGs) produced by an enzyme system, namely
prostaglandin-H2 synthetase (PGHS), which is composed
of two active sites: cyclo-oxygenase (COX) and per-
oxidase [2,3]. Indomethacin and ibuprofen are COX-
inhibitor drugs commonly used for the treatment of
hemodynamically significant (hs)-PDA. Despite the about
70% success rate, COX-inhibitors are frequently contra-
indicated in early life and their use has been associated
with serious adverse events, such as gastrointestinal per-
foration, renal failure and bleeding [4-11]. Paracetamol,
an inhibitor of the peroxidase component of PGHS, is
commonly used in pediatric age, and has been recently
proposed for the treatment of PDA [12-22]. We aimed
to evaluate the efficacy of paracetamol in the early* Correspondence: gianluca.terrin@uniroma1.it
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indication to COX-inhibitors.Case presentation
We report a case series of neonates with hs-PDA
treated with paracetamol because of contraindication
to ibuprofen or indomethacin, who were observed at the
Neonatal Intensive Care Unit of the University of Rome
“Sapienza”, from January 2012 to October 2013. During
this study period, based on our policy, neonates with ges-
tational age (GA) at birth < 32 weeks were evaluated daily
to detect the presence of hs-PDA. Neonates with hs-
PDA were treated with paracetamol in the presence
of contraindications to ibuprofen or indomethacin (i.e.
urine output < 1 ml/kg/h, intraventricular hemorrhage,
platelet count < 60,000/mm3, hyperbilirubinemia requir-
ing exchange transfusion, signs of feeding intolerance or
gastrointestinal bleeding). The condition of hs-PDA was
defined by the presence of at least one of the following
criteria: internal ductal diameter ≥ 1.5 mm, left-atrium-
to-aortic-root ratio > 1.6, unrestrictive pulsatile transduc-
tal flow, reverse or absent diastolic flow in the descending
aorta [23]. Paracetamol was given at doses ranging from
7.5 to 15 mg/kg every 4–6 hours, with a maximum dailytd. This is an Open Access article distributed under the terms of the Creative
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Table 1 Main demographic, clinical and echocardiographic
findings of preterm neonates before treatment with
paracetamol
Characteristics at baseline
Demographic and clinical features
N. 8
Body weight at birth, g 724 ± 173
Gestational age at birth, weeks 26 ± 2
Caesarian section, n (%) 6 (75.0)
Male, n (%) 6 (75.0)
Apgar at 5 minutes 5 ± 1
Resuscitation at birth, n (%) 8 (100)
Body weight at enrollment, g 743.7 ± 167.6
Age at enrollment, h 66 ± 28
Contraindication to COX-inhibitors
Oliguria, n (%) 4 (50.0)
Thrombocytopenia, n (%) 2 (25.0)
Intraventricular hemorrhage, n (%) 1 (12.5)
Blood in gastric aspirates, n (%) 1 (12.5)
Hyperbilirubinemia requiring phototherapy, n (%) 4 (50.0)
Hyperbilirubinemia requiring exchange transfusion, n (%) 0 (0.0)
Echocardiographic findings
Diameter of the ductus≥ 1.5 mm, n (%) 3 (37.5)
Left-atrium-to-aortic-root ratio > 1.6, n (%) 6 (75.0)
Unrestrictive pulsatile transductal flow, n (%) 1 (12.5)
Reverse flow in the descending aorta, n (%) 2 (25.0)
Notes. Data are expressed as mean ± standard deviation, when not specified.
Table 2 Serum level of liver enzymes and bilirubin before
and after treatment with paracetamol




Alanine aminotransferase, U/L 56 (8-78) 55 (4-78) 0.878
Aspartate aminotransferase, U/L 54 (26-80) 31 (8-62) 0.015
Bilirubinemia, mg/dl 7.6 (3.4-12.8) 5.0 (2.7-7.5) 0.050
Notes. Data are expressed as median (range: upper - lower values).
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form, data regarding GA, sex, mode of delivery, birth
weight (BW), Apgar score at 5 minutes, weight at enroll-
ment, age at enrollment, contraindication to COX-
inhibitor use and echocardiographic characteristics of
PDA before and after therapy, obtained from the clinical
charts and nursing records. Efficacy was defined by
the rate of patients in whom we observed ductal closure
(defined by the absence of shunt or diameter < 0.5 mm
without any other hemodynamic implications) at echo-
cardiographic examination performed daily during the
study period. To monitor safety of paracetamol treat-
ment, we collected data regarding serum concentration
of liver enzymes, total and direct bilirubin, creatinine and
urea nitrogen. Occurrence of common morbidities of
prematurity (i.e. bronchopulmonary dysplasia, intra-
ventricular hemorrhage, necrotizing enterocolitis), fatal
events and side effects were also collected. The study was
approved by the ethics committee of University of Rome
La Sapienza. The χ2 test and Fisher’s exact test were used
for categorical variables. The level of significance for all
statistical tests was 2-sided, p < 0.05. Statistical analysis
was performed with SPSS Version 16.0 for Windows
(SPSS Inc., Chicago, IL).
During the study period we observed 8 neonates
treated with paracetamol for an hs-PDA. Successful clos-
ure was obtained in 6 out of 8 neonates. Median ductal
diameter was significantly reduced after treatment (from
1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm,
p = 0.038). Baseline clinical findings, contraindications to
COX-inhibitors and echocardiographic characteristics of
our study population are reported in Table 1.
The two patients in whom paracetamol failed to close
the ductus, intravenous ibuprofen (at a dose of 10 mg/kg
followed by 5 mg/kg after 24 and 48 hours) was given
considering that previous contraindications were no lon-
ger present. Surgical ligation was finally needed for both
patients after ibuprofen failure. None of our patients
experienced re-opening of the ductus after closure. No
adverse or side effects were observed during treatment
(Table 2). One of the 2 patients who failed treatment with
paracetamol developed bronchopulmonary dysplasia.
Conclusions
Our case series demonstrates the efficacy of paracetamol
in hs-PDA in preterm neonates with contraindication to
COX inhibitors. Nine case series involving a total num-
ber of 67 neonates treated with paracetamol for PDA,
have been previously reported [12-20]. The larger series
evaluating efficacy of paracetamol in a similar setting,
included a maximum number of 10 patients [13,16,20].
Six studies verified the efficacy of paracetamol in very
low birth weight neonates [12,13,16,17,19,20]; four of them
reported a rate of ductal closure of 71-100% [12,13,16,17],while 2 series observed a very low efficacy rate (i.e. 0-20%)
[19,20]. In particular, Alan S. et al. reported the failure of
paracetamol in 3 neonates treated with this drug after one
or more unsuccessful courses of ibuprofen [19]. In the case
series reported by Roofthooft et al., paracetamol was inef-
fective in 8 out of 10 neonates [20]; however, these patients
had a lower GA and BW [20] and started paracetamol
treatment later [19,20] than the patients in our case series.
All these data suggest that lower GA and BW associated
with previous courses of ibuprofen or later ductal treat-
ment may negatively influence the response to paracetamol
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treatment in 2 subjects with very low GA. On the other
hand, the high rate of ductal closure observed in our popu-
lation could be associated with the earlier start of paraceta-
mol treatment compared with the vast majority of the
previous reports.
In five previous studies, paracetamol was administered
by enteral route [12,14-16,18] and in 4 by intravenous
route [13,17,19,20]. All of our patients were given para-
cetamol intravenously because they presented signs of
feeding intolerance (i.e., gastric residuals, vomiting, ab-
dominal distension). Even if parenteral route is associated
with higher peak and less variability of plasma concentra-
tion [27], apparently a similar rate of ductal closure was
observed also in reports using oral paracetamol. High
doses (60 mg/kg/day) of paracetamol were used in 7 out of
9 previous studies [12-15,18-20], while 2 studies reported
the administration of lower doses of paracetamol (30–
45 mg/kg/day), apparently without any reduction in effi-
cacy [16,17]. However no study comparing different dosing
regimens is available at the moment.
The mechanism of action of paracetamol remains
largely uninvestigated. Paracetamol, by inhibiting PG
production [3], firstly induces smooth muscle constric-
tion and narrowing of the lumen, similarly to COX-
inhibitors. In the subsequent phases of ductal closure,
platelet aggregation plays a crucial role in the forma-
tion of a thrombus that occludes ductal lumen [28,29].
A lower anti-platelet activity of paracetamol compared
to that of COX-inhibitors may positively influence this
phase of the closure process [3]. In any case, future
studies should be performed to shed light on the mode
of action of paracetamol.
Although interesting, the results of our study suffer
from some limitations. Similarly to previous case series,
ours is based on a limited number of neonates. Recently,
two randomized clinical trials have demonstrated similar
efficacy of oral paracetamol compared with oral ibupro-
fen [21,22]. Although interesting, results of these trials
do not clarify many aspects related to paracetamol use
in neonatal age (i.e., optimal dosage, time to start ther-
apy and route of administration). In addition these trials
present significant limitations such as inadequate sample
power calculation and absence of per intention-to-treat
analysis. Pharmacokinetic studies were not performed in
our population to avoid adjunctive procedures and blood
collections in preterm infants at high risk of iatrogenic
anemia [30,31]. Nevertheless previous studies have dem-
onstrated that the doses used in our study are safe and
associated with optimal levels of serum paracetamol
concentrations [13].
Our results encourage further well designed studies
aimed at verifying the efficacy of paracetamol also as
first choice agent in the treatment of PDA.Consent
Written informed consent was obtained from the parents
of the patients for the publication of this report.
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